This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish (read more).

Clinical Services

Analytical Services

PCI provides fully audited, in-house laboratories in both our European and North America locations offering a range of analytical services to support clients in the development and commercialization of new medicines.

Staffed with expertly qualified analytical chemists, trained and accredited in the most comprehensive laboratory standards, we provide a complete range of resources and responsive services at each stage of the product lifecycle across a wide variety of dosage forms.

Our state-of-the-art facilities feature best-in-class and fully GMP and ICH compliant equipment enabling our teams to perform simple ID testing and analytical method transfers, through method development and validation, to EU product release and ICH stability testing, ensuring data reliability and regulatory compliance.

Our facilities also include HEPA filtered air handling systems for the analysis of cytotoxic, teratogenic and uncharacterized products, a darkroom for the analysis of light sensitive products, and the capabilities to work with Schedule II-IV controlled substances.

Anaytical services are offered on a stand-alone basis or in conjunction with our clinical, commercial and QP services to facilitate a seamless transmission through the drug development cycle.

Our dedicated team of specialists will be happy to discuss any of our Analytical Services with you. Contact us on +1 779-774-1428 (US) or +44 1495 711 222 (UK) or email sales@pciservices.com


Expansion of High Potent Tableting and Powder Modification Capacity

Investment in new technologies at PCI’s global manufacturing Center of Excellence in Tredegar, Wales, to double highly potent tableting capacity... View Article

PCI Welcomes New Chief Financial Officer and SVP, Serge Dupuis

PCI is pleased to welcome Serge Dupuis as Senior Vice President and Chief Financial Officer. Serge’s appointment supports PCI’s continued... View Article

x